Published in Medical Letter on the CDC and FDA, November 18th, 2007
The new HIV drug, generically known as Raltegravir, is an HIV integrase inhibitor. Integrase inhibitors prevent replication of the virus by blocking insertion of HIV genetic material into human DNA. There are several other HIV integrase inhibitor drugs under development.
Isentress clinical trials researchers followed patients' progress by testing their viral loads with Roche's COBAS(R)HIV-1 AMPLICOR viral load test, which targets the gag region of the HIV virus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.